Pharming Group NV (NASDAQ:PHAR) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET
Company Participants
Sijmen de Vries - CEO & Executive Director
Stephen Toor - Chief Commercial Officer
Anurag Relan - Chief Medical Officer
Jeroen Wakkerman - CFO
Conference Call Participants
Sushila Hernandez - Van Lanschot Kempen
Jeff Jones - Oppenheimer
Alistair Campbell - RBC Capital Markets
Simon Scholes - First Berlin
Sijmen de Vries
Good morning or good afternoon, ladies and gentlemen; I'm here. Next slide, please. Welcome to our results conference for the first half and second quarter of this year. And I'm here with my colleagues, Stephen Toor, our Chief Commercial Officer; Anurag Relan, our Chief Medical Officer; and Jeroen Wakkerman, our Chief Financial Officer who will -- we will collectively guide you through the story.
But before I do that, I would like to have this next slide and point you to these forward-looking statement slide. So we will be making forward-looking statements in this presentation. And as you well know, these are based upon our -- upon future expectations that are based on our current expectations and assumptions, and may involve known and unknown risks and uncertainties. As you well know, the results eventually could differ materially from what we have expressed or implied in our statements. Next slide, please.
And then, you can immediately move on to slide number 5, please. So what we're doing is -- this is the strategy that we've been embarked on for quite some time now. We're building this leading global rare disease biopharma company. And we do that on the basis of two strong pillars.
The first one on the left, of course, is RUCONEST, which has now been on the market for close to 10 years in the US, and of course, deliver sales mainly from the market. And we were very pleased to see that RUCONEST continues to grow very significantly, both in context of the comparison to the previous quarters -- in the second quarter, 23% versus last year; and both when you compare the first half to last year's first half, 16% which is, I would say, a very strong performance, which we're very pleased with.
And Stephen will, a little bit later, give you more details on the underlying positive indicators also going forward into the second half of the year. And then, of course, we have to Joenja, which we launched last year in end of -- which was approved end of March last year, which we brought into the market beginning of the second quarter of last year. And we're very pleased to see that this continues to grow as well.